Payment overview · 2025
General Payments
$149.55
8 reported records · 4 companies
Healthcare provider profile · identity verified
Adam David Amos, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENCASTLE, IN · NPI 1407122666
Verified facts
What the public records show
CMS Open Payments records show Adam David Amos, MD received $149.55 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.06 | 41.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.37 | 35.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.78 | 11.9% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $17.34 | 11.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $149.55 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.06 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.37 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $17.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 112 |
| Lisinopril | Lisinopril | 300 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 60 |
| Omeprazole | Omeprazole | 240 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 192 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 48 |
| Gabapentin | Gabapentin | 163 | 38 |
| Losartan Potassium | Losartan Potassium | 163 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 20 |
| Jardiance | Empagliflozin | 100 | 22 |
| Metformin Hcl | Metformin Hcl | 97 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 24 |
| Montelukast Sodium | Montelukast Sodium | 93 | 26 |
| Eliquis | Apixaban | 90 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 26 |
| Glipizide Er | Glipizide | 80 | 21 |
| Metformin Hcl Er | Metformin Hcl | 79 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 22 |
| Furosemide | Furosemide | 73 | 29 |
| Simvastatin | Simvastatin | 73 | 21 |
| Sertraline Hcl | Sertraline Hcl | 69 | 16 |
| Tramadol Hcl | Tramadol Hcl | 69 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 12 |
| Mounjaro | Tirzepatide | 66 | 14 |
| Prednisone | Prednisone | 65 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 64 | 18 |
| Carvedilol | Carvedilol | 63 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 63 | suppressed |
| Famotidine | Famotidine | 60 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 16 |
| Trazodone Hcl | Trazodone Hcl | 58 | 14 |
| Januvia | Sitagliptin Phosphate | 54 | 11 |
| Spironolactone | Spironolactone | 53 | 12 |
| Potassium Chloride | Potassium Chloride | 51 | 16 |
| Buspirone Hcl | Buspirone Hcl | 50 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 11 |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 13 |
| Alprazolam | Alprazolam | 46 | suppressed |
| Nystatin | Nystatin | 46 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 14 |
| Meloxicam | Meloxicam | 42 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Allopurinol | Allopurinol | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 27 |
| Fluconazole | Fluconazole | 29 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 23 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 11 |
| Nitroglycerin | Nitroglycerin | 26 | 14 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 14 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Ramelteon | Ramelteon | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $149.55 · 8 records | ABBVIE INC. | Azstarys, CAPLYTA, MOUNJARO, VRAYLAR, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error